128 results about "Opioidergic" patented technology

Described are compositions and methods for increasing opioid therapy efficacy and ameliorating opioid use disorder. The compositions and methods target Ptchd1 or neuronal cholesterol.

Described are compositions and methods for treating pain and / or increasing opioid therapy efficacy and ameliorating opioid use disorder. The compositions and methods target Gαg / 11 signaling.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

Nicotine delivery devices and systems, particularly smoking cessation systems are provided by the present disclosure. Such devices and systems produce a nicotine-containing aerosol for inhalation that mimics smoking. The devices are capable of being adapted to control the amount of nicotine delivered to taper the amount of nicotine delivered to the user over time. Methods for treating patients to stop smoking are also disclosed. The devices, systems and methods can also be used to deliver other drugs disclosed herein, such as opioids (e.g., fentanyl).

Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist. Methods and compositions are also provided for treating individuals exhibiting opioid withdrawal symptoms or prophy tactically treating individuals for opioid withdrawal symptoms from opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of withdrawal, including respiratory depression, sedation, and hypotension.

A portable emergency response kit designed for rapid intervention in opioid overdose or cardiac arrest scenarios comprises a durable case with compartments for specific medical devices, such as opioid overdose treatment medication or an Automated External Defibrillator (AED). The case features a breakable closed circuit that is, upon opening, triggered to send a signal to notify emergency medical services (EMS) or predefined contacts of the kit's location.The system utilizes GPS module and may include dual-mode communication capabilities for reliable alert transmission in various environments. Additional features may include a transparent case material for visual confirmation of contents, tamper-evident seals, QR codes linked to instructional content, and a battery power source. The kit is designed to be user-friendly, incorporating ergonomic elements and optional accessories for enhanced portability and storage, ensuring rapid and effective response in critical situations.

The disclosure is directed at an abuse-deterrent pharmaceutical composition comprising a coated antagonist particle, and the use thereof for preventing or minimizing the risk of opioid abuse and / or opioid toxicity from either intentional or unintentional tampering. Methods for manufacturing such an abuse-deterrent pharmaceutical composition are also provided.

Methods and apparatuses for opioid overdose prevention are described. The apparatus comprises a memory and at least one processor coupled to the memory. The processor is configured to receive one or more measurements related to one or more vitals of a user, and cause, based on the one or more measurements, administration of a first dose of an overdose prevention medication to the user.

The invention system is a wearable device that detects an impending or onset of cardio-respiratory arrest and remediates the condition by injecting an appropriate reversal drug depending upon the drug that triggered the arrest. It can detect and remediate arrests caused by drugs such as opioids, benzodiazepine or alcohol. Using self-test and other checks, it ensures that the system is operationally ready and that no near-expiration or expired drug is administered.

The application discloses application of a peripheral nervous system Mas-related G protein-coupled receptor D as a target point in preparation of a medicine for screening for relieving opioid tolerance. Jun The application further provides a medicine composition for regulating opioid tolerance, containing a Mas-related G protein-coupled receptor D siRNA sequence shown in SEQ ID NO. 1 or a siRNA sequence shown in SEQ ID NO. 2. The application further provides an in-situ hybridization kit for detecting expression of a Mas-related G protein-coupled receptor D gene in a dorsal root ganglion tissue of a peripheral nervous system. The application expands a new path for opioid companion diagnosis and intervention.

A compound having a structure of formula (I), (II), (III), (IV), (V), (VI), or a pharmaceutically acceptable salt, a tautomer, or a solvate thereof for use in treating opioid addiction, withdrawal and / or dependence and / or loss of opioid induced analgesia and / or occurrence of opioid induced hyperalgesia in a subject in need thereof.

A method comprises acquiring a plurality of multimodal physiological signals, dividing the plurality of multimodal physiological signals into a plurality of sliding windows containing a respective multimodal physiological signal, selecting a subset of the plurality of sliding windows that contain the respective multimodal physiological signal, modifying the respective multimodal physiological signal contained in the subset of the plurality of sliding windows; providing, as one or more inputs to a machine learning model, the plurality of sliding windows that contain the respective multimodal physiological signal and the subset of the plurality of sliding windows that contain the respective modified multimodal physiological signal; and identifying, using one or more outputs of the machine learning model, at least one moment of opioid administration.

The invention discloses application of a peripheral nervous system Mas related G protein coupled receptor D as a target spot in preparing and screening a medicine for relieving opioid medicine tolerance. The invention also provides a pharmaceutical composition for regulating and controlling the tolerance of the opioid drugs. The pharmaceutical composition contains a Mas related G protein coupled receptor D siRNA sequence as shown in SEQ ID NO. 1 or a Jun siRNA sequence as shown in SEQ ID NO. 2. The invention also provides an in-situ hybridization kit for detecting the expression of the Mas related G protein coupled receptor D gene in the dorsal root ganglion tissue of the peripheral nervous system. According to the invention, a new path for accompanying diagnosis and intervention of opioid drugs is expanded.

To provide compounds and compositions for reducing most common opioid-induced hyperalgesia associated with microglial hyperactivation.SOLUTION: 2-pentadecyl-2-oxazoline (PEA-OXA) for use as an opioid adjuvant for preventing the development of or in the treatment of opioid-induced hyperalgesia (OIH), wherein the PEA-OXA is administered with or in combination with an opioid. Wherein the administration is separate, together or simultaneous.SELECTED DRAWING: None

A composition for the treatment of chronic pain and mixed pain sites may include a serotonin and norepinephrine reuptake inhibitor; a non-steroidal anti-inflammatory agent; optionally acetaminophen; optionally oxcarbamazepine; optionally an oral opioid antagonist; optionally an antacid; optionally an anti-epileptic; and optionally an opioid. A method for treating chronic pain and mixed pain sites may include administering, to a patient in need, a therapeutically effective dosage of the composition.

Methods and compounds to therapeutically treat a molecular target to counteract circuit adaptations of long-term opioid use that are associated with a functional disability and negative affect in both CBP−O (chronic back pain managed without opioids) and CBP+O (chronic back pain managed with opioids).

A method, apparatus and computer program product are provided for a compiled standardized measure representative of a subset of prescription transactions associated with a controlled substance. The compiled standardized measures may be used in the prescription domain to notify prescribers of a patient's morphine milligram equivalent (MME) to reduce risks related to drug overdose, abuse, and the like. Historical prescription transactions may be accessed to identify prescriptions classified as an opioid or other controlled substance, and that may likely still be in a patient's possession based upon days supply, such that a daily MME may be calculated. Messaging is provided to the prescriber if the amount exceeds a maximum threshold, and the prescription can be changed accordingly.

2-Pentadecyl-2-oxazoline (also known as palmitoylethanolamide oxazoline or PEA-OXA) is used to counteract hyperalgesia induced by the most common opioids (OIH) associated with microglial hyperactivation. In particular, PEA-OXA is administered to humans and animals to prevent or treat some of the adverse effects of opioids by controlling immune hyperactivation. The PEA-OXA is administered separately, sequentially or jointly with the opioid.

A wearable device is provided for recognition and response to an overdose, such as an opioid overdose. The device includes an oximetry sensor for measuring peripheral oxygen saturation (SpO2) of a wearer of the wearable device and a motion sensor for determining whether the wearer of the wearable device is moving or motionless. The wearable device further includes an injector including a supply of an antidote and a needle for intramuscular delivery of the antidote to the wearer of the wearable device. The wearable device may also include a housing in which the oximetry sensor, the motion sensor, and the supply of the antidote is contained and in which the needle is initially contained in a retracted condition. The wearable device may further include a strap extending from the housing and sized to secure the housing on an upper arm of the wearer adjacent the shoulder of the wearer.

The invention provides a cyclic ketone compound and a medical effect thereof, and belongs to the technical field of anesthetic drugs. The cyclic ketone compound is a compound as shown in a formula (I), or a stereoisomer thereof, or a deuterated derivative thereof, or a prodrug thereof, or a salt thereof, or a solvate thereof. It is found that the cyclic ketone compound and the prodrug thereof can significantly improve respiratory depression caused by anesthesia and / or sedative, and can improve the respiratory function in inhalation general anesthesia retaining spontaneous respiration; meanwhile, compared with sodium camphorsulfonate and oxycamphor, the compound disclosed by the invention can obviously improve respiratory depression induced by opioids at a lower dosage, the minimum dosage for inducing adverse reactions is higher, and the safety is better. The invention has a good improvement effect on respiratory depression caused by opioids and inhalation anesthetics, provides a new solution for respiratory depression caused by clinical anesthesia, and has a wide application prospect.

The invention relates to the technical field of gene detection, in particular to an opioid analgesic drug gene detection method based on multiple targeted amplification, which comprises the following steps: extracting DNA from a peripheral blood sample; the method comprises the following steps: setting a primer pool aiming at a preset site of a specific gene related to opioid drugs, and carrying out multi-targeted amplification sequencing by using the primer pool to obtain sequencing data; comparing the sequencing data with a human reference genome to obtain a data comparison rate, and judging the eligibility of the multi-target amplification sequencing process according to the data comparison rate; performing variation detection on the qualified sequencing data, identifying the base type of each SNP site, and determining the genotype of the subject in combination with a dbSNP database; and inputting the genotype and clinical data into a pre-trained multi-gene prediction model, and obtaining the medication guidance of the subject for using the opioid drugs. The gene detection efficiency is improved.

The present invention relates to a pharmaceutical composition for treating drug addiction comprising opioid receptor nanodiscs and to a method for preparing opioid receptor nanodiscs. Specifically, the opioid receptor nanodiscs, according to the present invention, inhibit the interaction between an opioid receptor and an opioid-based drug without exhibiting toxicity in the body, are delivered to the brain when administered into the body, and significantly restore the delay in a hot-plate response caused by opioid-based drug addiction, thereby being usefully applicable to treatment of opioid-based drug addiction.

The present invention relates to novel peptides, compositions and uses thereof in tissue penetration, in particular in the context of cancer prevention and / or treatment or induction of an immune response, in particular mucosal vaccination or anti-opioid treatment.

The present disclosure provides a naloxone film product for treatment and prevention of opioid overdoses. Also provided is a method of making the film product. The film product comprises a naloxone composition and at least one polymer.

Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.

The aspects of the disclosed embodiments introduce a novel class of bioactive compounds, including short peptides and peptidosteroids, designed for the selective modulation of G-Protein Coupled Receptors (GPCRs), with a particular focus on the human mu-opioid receptor (MOR). These compounds feature specific amino acid sequences and modifications such as acylation and covalent steroid modifications, including 3beta-hydroxy-5-cholenoic acid or other fatty acid derivatives. These modifications enhance stability, membrane affinity, receptor selectivity, and allosteric modulation potential. The aspects of the disclosed embodiments provide a platform for receptor-targeted therapies, particularly for chronic pain conditions such as neuropathic pain, cancer-related pain, and postoperative pain. By biasing MOR signaling toward analgesic pathways and reducing adverse effects, these compounds address the limitations of traditional opioid therapies, offering improved safety, efficacy, and bioavailability. The described peptides and peptidosteroids also exhibit potential for broader GPCR-mediated therapeutic applications, establishing their utility in advancing precision pharmacology.

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when opioid induced respiratory depression is detected. The system and methods include a wearable device that acquires physiological and other information from an opioid user during an opioid use session, analyzes the information to detect the presence of opioid induced respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.

The present disclosure provides methods and compositions for reducing the addictive liability of opioid analgesics in a subject, for example, by co-administering to the subject the opioid and a serotonin receptor type 2 (5HT2) agonist or a serotonin (5HT) releasing agent. The disclosed methods include methods for preventing opioid abuse, methods for reducing the rewarding effect of an opioid, methods for reducing the addictive liability of an opioid, methods for eliminating or substantially reducing the tendency for a subject to develop physical dependence, tolerance, and / or withdrawal symptoms with respect to an opioid, and methods for eliminating or substantially reducing the tendency for a subject to use opioids in ways not prescribed, take opioids more often or in larger amounts than prescribed, and / or use opioids recreationally. The methods can be performed on a subject, such as a patient (e.g., a human patient).

Naloxone variants that are both long lasting and responsive are disclosed. One version of the compound has a boron ester functional group and the antagonist compound is capable of a sustained release of antagonist based on reaction with hydrogen peroxide. In addition, a method of treating opioid overdose is disclosed. The method involves administering a therapeutically effective amount of the formulation described above to a patient in need thereof. Administration occurs either intranasally, sublingually or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly.

The present disclosure pertains to a method of detecting an opioid in a sample by (1) determining a butyrylcholinesterase inhibition activity of the sample; and (2) correlating the butyrylcholinesterase inhibition activity of the sample to the presence or absence of opioid in the sample, where no relative inhibition of butyrylcholinesterase activity is correlated to the absence of opioid in the sample, and where a relative inhibition of butyrylcholinesterase activity is correlated to the presence of opioid in the sample. The present disclosure also pertains to assays for detecting opioid in a sample in accordance with the methods of the present disclosure.